{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T18:13:29Z","timestamp":1769278409762,"version":"3.49.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>It is not known how the 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy predicts clinical course of \u03b11-antitrypsin deficiency (AATD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine how the new strategy relates to outcomes (i.e., mortality, lung function decline, and exacerbations) in patients with AATD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All PiZZ patients (patients with ZZ genotype causing severe AATD) on the AATD registry with a physiological diagnosis of chronic obstructive pulmonary disease were grouped into four GOLD categories (A, B, C, and D) on the basis of their combined risk. We then compared mortality and lung function decline in these categories and also assessed the predictive ability of exacerbation history in the patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Mortality (GOLD categories A: 6 [5.8%]; B: 7 [5.93%]; C: 11 [9.32%]; D: 94 [79.66%]) was greatest in high-symptom, high-risk category D (P = 0.0001), which also showed a faster decline in Kco (mmol\/min\/kPa\/L\/yr, mean [SD], A: \u22120.021 [0.03]; B: \u22120.022 [0.03]; C: \u22120.032 [0.03]; D: \u22120.031 [0.03]) (P = 0.012). The fastest mean decline in FEV1 (ml\/yr, mean [SD], A: \u221266.59 [61.39]; B: \u221253.00 [47.09]; C: \u221256.96 [48.87]; D: \u221241.25 [62.09]) was observed in category A and least in category D (P = 0.002). Multivariate analysis showed that GOLD category was significant for all outcomes (P &amp;lt; 0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The new strategy performs well in identifying patients with increased risk of poorer outcomes in AATD. This has therapeutic implications enabling more aggressive therapy to be directed to those in the highest-risk group. Further studies to identify subgroups of patients most likely to benefit from augmentation therapy are indicated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.201311-380oc","type":"journal-article","created":{"date-parts":[[2014,6,20]],"date-time":"2014-06-20T11:45:43Z","timestamp":1403264743000},"page":"859-864","source":"Crossref","is-referenced-by-count":8,"title":["Relationship of the 2011 Global Initiative for Chronic Obstructive Lung Disease Strategy to Clinically Relevant Outcomes in Individuals with \u03b11-Antitrypsin Deficiency"],"prefix":"10.1093","volume":"11","author":[{"given":"Anilkumar P.","family":"Pillai","sequence":"first","affiliation":[{"name":"University Hospitals, Birmingham, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice M.","family":"Turner","sequence":"additional","affiliation":[{"name":"University of Birmingham, Birmingham, United Kingdom; and"},{"name":"Respiratory Medicine, Heart of England NHS Foundation Trust, Birmingham, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Stockley","sequence":"additional","affiliation":[{"name":"University Hospitals, Birmingham, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,7,1]]},"reference":[{"key":"2026012303545691100_bib1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary","volume":"187","author":"Vestbo","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303545691100_bib2","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1378\/chest.13-0161","article-title":"Global Initiative for Chronic Obstructive Lung Disease 2011 symptom\/risk assessment in \u03b11-antitrypsin deficiency","volume":"144","author":"Pillai","year":"2013","journal-title":"Chest"},{"key":"2026012303545691100_bib3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.201207-1299OC","article-title":"Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population","volume":"186","author":"Lange","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303545691100_bib4","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/thorax.58.12.1020","article-title":"Predictors of mortality in alpha1-antitrypsin deficiency","volume":"58","author":"Dawkins","year":"2003","journal-title":"Thorax"},{"key":"2026012303545691100_bib5","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1164\/ajrccm.160.5.9901055","article-title":"A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy","volume":"160","author":"Dirksen","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303545691100_bib6","first-page":"363","article-title":"Genetic variants of alpha 1-antitrypsin","volume":"10","author":"Laurell","year":"1965","journal-title":"Vox Sang"},{"key":"2026012303545691100_bib7","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1164\/ajrccm.164.10.2106036","article-title":"Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline","volume":"164","author":"Dowson","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303545691100_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1164\/rccm.201106-0992OC","article-title":"Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease","volume":"185","author":"Nishimura","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303545691100_bib9","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1164\/ajrccm.157.5.9709032","article-title":"Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease","volume":"157","author":"Seemungal","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303545691100_bib10","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1183\/09031936.05.00074704","article-title":"Exacerbations in {alpha}1-antitrypsin deficiency","volume":"25","author":"Needham","year":"2005","journal-title":"Eur Repir J"},{"key":"2026012303545691100_bib11","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A 4-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N Engl J Med"},{"key":"2026012303545691100_bib12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"key":"2026012303545691100_bib13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/15412550902905961","article-title":"Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis","volume":"6","author":"Chapman","year":"2009","journal-title":"COPD"},{"key":"2026012303545691100_bib14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7326\/0003-4819-106-2-196","article-title":"Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease","volume":"106","author":"Anthonisen","year":"1987","journal-title":"Ann Intern Med"},{"key":"2026012303545691100_bib15","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1183\/09031936.00061208","article-title":"Rate of progression of lung function impairment in alpha1-antitrypsin deficiency","volume":"33","author":"Dawkins","year":"2009","journal-title":"Eur Respir J"},{"key":"2026012303545691100_bib16","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1164\/rccm.200406-761OC","article-title":"Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences lung function impairment","volume":"170","author":"Parr","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303545691100_bib17","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1164\/ajrccm.152.3.7663812","article-title":"Gender effect on prognosis of patients receiving long-term home oxygen therapy","volume":"152","author":"Miyamoto","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303545691100_bib18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1164\/ajrccm.158.3.9801093","article-title":"Sex differences in mortality of people who visited emergency rooms for asthma and chronic obstructive pulmonary disease","volume":"158","author":"Sunyer","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303545691100_bib19","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/thorax.57.10.847","article-title":"Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease","volume":"57","author":"Donaldson","year":"2002","journal-title":"Thorax"},{"key":"2026012303545691100_bib20","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1378\/chest.07-0341","article-title":"Radiologic and clinical features of COPD patients with discordant pulmonary physiology: lessons from alpha1-antitrypsin deficiency","volume":"132","author":"Holme","year":"2007","journal-title":"Chest"},{"key":"2026012303545691100_bib21","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N Engl J Med"},{"key":"2026012303545691100_bib22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0025-7125(16)31509-7","article-title":"An overview of obstructive lung diseases","volume":"65","author":"Burrows","year":"1981","journal-title":"Med Clin North Am"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/11\/6\/859\/66552199\/annalsats_11_6_859.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/11\/6\/859\/66552199\/annalsats_11_6_859.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:55:07Z","timestamp":1769158507000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/11\/6\/859\/8432219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,1]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,7,1]]},"published-print":{"date-parts":[[2014,7,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.201311-380oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,7]]},"published":{"date-parts":[[2014,7,1]]}}}